Search research articles
Contact Us
Filters
Showing results (61-70 of 117) with videos related to
Page
of 12
Sort By:
Haematologica
|
October 14, 2021
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
Marcelo Capra, Thomas Martin, Philippe Moreau, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 8, 2015
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial
Katja Weisel, Meletios Dimopoulos, Kevin W Song, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 31, 2016
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma
David S Siegel, Meletios Dimopoulos, Sundar Jagannath, et al.
The Oncologist
|
February 28, 2016
The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective
Jo Caers, Carlos Fernández de Larrea, Xavier Leleu, et al.
Blood Advances
|
December 7, 2020
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma
Nikhil C Munshi, Herve Avet-Loiseau, Kenneth C Anderson, et al.
Leukemia & Lymphoma
|
April 29, 2016
A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation
Katja Weisel, Chantal Doyen, Meletios Dimopoulos, et al.
Blood
|
October 20, 2020
Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma
Meletios Dimopoulos, Sara Bringhen, Pekka Anttila, et al.
Blood Vessels, Thrombosis & Hemostasis
|
March 11, 2026
On a quest for fingerprints of crystalglobulinemia on platelets and endothelium
Vasiliki Gkalea, Panagiota-Efstathia Nikolaou, Thomas Pappas, et al.
Breast Cancer Research and Treatment
|
July 11, 2006
Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival
Lida Kostadima, George Pentheroudakis, George Fountzilas, et al.
Cancer Medicine
|
February 29, 2020
Once-weekly (70 mg/m<sup>2</sup> ) vs twice-weekly (56 mg/m<sup>2</sup> ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials
Philippe Moreau, Keith A Stewart, Meletios Dimopoulos, et al.
Page
of 12
Search research articles
Search
Showing results (61-70 of 117) with videos related to
Sort By:
Page
of 12
Haematologica
|
October 14, 2021
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
Marcelo Capra, Thomas Martin, Philippe Moreau, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 8, 2015
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial
Katja Weisel, Meletios Dimopoulos, Kevin W Song, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 31, 2016
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma
David S Siegel, Meletios Dimopoulos, Sundar Jagannath, et al.
The Oncologist
|
February 28, 2016
The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective
Jo Caers, Carlos Fernández de Larrea, Xavier Leleu, et al.
Blood Advances
|
December 7, 2020
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma
Nikhil C Munshi, Herve Avet-Loiseau, Kenneth C Anderson, et al.
Leukemia & Lymphoma
|
April 29, 2016
A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation
Katja Weisel, Chantal Doyen, Meletios Dimopoulos, et al.
Blood
|
October 20, 2020
Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma
Meletios Dimopoulos, Sara Bringhen, Pekka Anttila, et al.
Blood Vessels, Thrombosis & Hemostasis
|
March 11, 2026
On a quest for fingerprints of crystalglobulinemia on platelets and endothelium
Vasiliki Gkalea, Panagiota-Efstathia Nikolaou, Thomas Pappas, et al.
Breast Cancer Research and Treatment
|
July 11, 2006
Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival
Lida Kostadima, George Pentheroudakis, George Fountzilas, et al.
Cancer Medicine
|
February 29, 2020
Once-weekly (70 mg/m<sup>2</sup> ) vs twice-weekly (56 mg/m<sup>2</sup> ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials
Philippe Moreau, Keith A Stewart, Meletios Dimopoulos, et al.
Page
of 12